Woodward R&D increased by 22.2% to $46.12M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 23.9%, from $37.23M to $46.12M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 6.0% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $29.77M | $27.70M | $25.39M | $32.38M | $32.22M | $29.78M | $28.63M | $37.78M | $35.03M | $32.06M | $30.79M | $36.47M | $38.73M | $34.69M | $30.21M | $37.23M | $41.09M | $39.04M | $37.76M | $46.12M |
| QoQ Change | — | -6.9% | -8.3% | +27.5% | -0.5% | -7.6% | -3.9% | +31.9% | -7.3% | -8.5% | -4.0% | +18.4% | +6.2% | -10.4% | -12.9% | +23.2% | +10.4% | -5.0% | -3.3% | +22.2% |
| YoY Change | — | — | — | — | +8.3% | +7.5% | +12.8% | +16.7% | +8.7% | +7.7% | +7.5% | -3.5% | +10.5% | +8.2% | -1.9% | +2.1% | +6.1% | +12.6% | +25.0% | +23.9% |
| Segment | Q1 '26 |
|---|---|
| Aerospace | $29.42M |
| Industrial | $14.91M |
| Total | $46.12M |